FINNENCE ▪ THE WIRE FILE
THE WIRE · № 83903
News▲ Bullish
The chairman bought 29,250 shares in CytoMed Therapeutics (NASDAQ: GDTC) and reported his stake.
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Chairman share purchase signals insider confidence, a mild positive for the small-cap.
Insider buying signals chairman confidence
CATALYST TO WATCH
Further insider filings
MAIN RISK
Micro-cap, minimal liquidity
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Rush-Endeavor merger faces a test over scale and insurer leverage2026-10-16 10:15 UTC
Rush-Endeavor merger faces a test over scale and insurer leverage2026-10-16 10:15 UTC
→CORRELATIONshares Healthcare
City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field2026-10-16 10:17 UTC
City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field2026-10-16 10:17 UTC
→CORRELATIONshares Healthcare
Extrawell Pharmaceutical Abandons Negotiations For Possible Sale Of Convertible Bonds2026-10-16 10:19 UTC
Extrawell Pharmaceutical Abandons Negotiations For Possible Sale Of Convertible Bonds2026-10-16 10:19 UTC
→CORRELATIONshares Healthcare
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)2026-10-16 11:12 UTC
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)2026-10-16 11:12 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.